US 12,247,081 B2
CEACAM5-dependent 4-1BB-agonistic bispecific antibodies
Runsheng Li, Shanghai (CN); Wei Cao, Shanghai (CN); Ying Qin Zang, Shanghai (CN); and Wentao Huang, Shanghai (CN)
Assigned to LANOVA MEDICINES LIMITED, Shanghai (CN)
Filed by LANOVA MEDICINES LIMITED, Shanghai (CN)
Filed on May 8, 2024, as Appl. No. 18/658,896.
Application 18/658,896 is a continuation of application No. PCT/CN2024/078991, filed on Feb. 28, 2024.
Prior Publication US 2024/0294656 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/3007 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/569 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. A bispecific antibody, comprising one or more anti-4-1BB single domain antibodies (VHH) and an anti-CEACAM5 antibody or antigen-binding fragment thereof, wherein the one or more anti-4-1BB single domain antibodies each comprises a complementarity determining region 1 (VHH CDR1), a VHH CDR2 and a VHH CDR3, wherein
(a) the VHH CDR1 comprises the amino acid sequence of SEQ ID NO: 21; the VHH CDR2 comprises the amino acid sequence of SEQ ID NO: 22 or 24, and the VHH CDR3 comprises the amino acid sequence of SEQ ID NO: 23; or
(b) the VHH CDR1 comprises the amino acid sequence of SEQ ID NO: 21 or 27; the VHH CDR2 comprises the amino acid sequence of SEQ ID NO: 25 or 28, and the VHH CDR3 comprises the amino acid sequence of SEQ ID NO: 26,
wherein the anti-CEACAM5 antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:34, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:35, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:36.